Professor Ernst Hafen is based at the Institute of Molecular Systems Biology at ETH Zurich. He studied the developmental and […]
The UKB-ESC research team has published a paper that explains how the collaboration between the UK Biobank and biopharmaceutical companies […]
Recently, researchers have developed a machine learning approach that can predict the fitness trajectories of cancer cells in response to […]
Despite an increase in investment into R&D from biopharma companies, only 5-10% of drugs that enter early-stage clinical trials ever […]
Clinical trials are used to determine the efficacy of a drug in patients. However, effective clinical trials that have a large […]
Epigenetic targets are of significant importance in drug discovery research, and there is increasing availability of chemogenomic data related to […]
A team of researchers have developed a personalized genomic medicine platform, My Personal Mutanome, that will help accelerate genome-informed cancer […]
Researchers have constructed a tumour-biomarker knowledge graph and used it to discover potential adverse drug reactions from antitumour drugs. Adverse […]
At the Festival of Genomics and Biodata, Paul Nioi (Senior Director, Research, Alnylam Pharmaceuticals) joined us to explore how population […]
The National Institutes of Health (NIH) have funded a five-year effort to use state-of-the-art artificial intelligence methods to study Alzheimer’s […]
